CN105218587B - A kind of lobaplatin crystal, preparation method and medicinal application - Google Patents
A kind of lobaplatin crystal, preparation method and medicinal application Download PDFInfo
- Publication number
- CN105218587B CN105218587B CN201410279550.1A CN201410279550A CN105218587B CN 105218587 B CN105218587 B CN 105218587B CN 201410279550 A CN201410279550 A CN 201410279550A CN 105218587 B CN105218587 B CN 105218587B
- Authority
- CN
- China
- Prior art keywords
- lobaplatin
- ether
- dihydrate
- crystal
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229950008991 lobaplatin Drugs 0.000 title claims abstract description 160
- 239000013078 crystal Substances 0.000 title claims abstract description 139
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- -1 lobaplatin dihydrate Chemical class 0.000 claims abstract description 89
- 238000002425 crystallisation Methods 0.000 claims abstract description 43
- 230000008025 crystallization Effects 0.000 claims abstract description 40
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 33
- 238000003756 stirring Methods 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000000725 suspension Substances 0.000 claims abstract description 18
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims abstract description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 29
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 21
- 238000001291 vacuum drying Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 7
- 238000001953 recrystallisation Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- FPJNQJHCHVUNTK-UHFFFAOYSA-N platinum;dihydrate Chemical compound O.O.[Pt] FPJNQJHCHVUNTK-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 238000004455 differential thermal analysis Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CLSIFQGHPQDTHQ-DTWKUNHWSA-N (2s,3r)-2-[(4-carboxyphenyl)methyl]-3-hydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC1=CC=C(C(O)=O)C=C1 CLSIFQGHPQDTHQ-DTWKUNHWSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DTPQZKZONQKKSU-UHFFFAOYSA-N silver azanide silver Chemical compound [NH2-].[Ag].[Ag].[Ag+] DTPQZKZONQKKSU-UHFFFAOYSA-N 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- YPUBCBDXROWIBU-UHFFFAOYSA-N platinum trihydrate Chemical compound [Pt].O.O.O YPUBCBDXROWIBU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical class CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of lobaplatin crystal, preparation method and medicinal applications, its crystal form is E, its fusing point Tm.p..=214 ± 5 DEG C, there is diffraction maximum at 2 θ angle value is 6.61,8.09,12.38,13.03,15.40,16.66,17.47,19.07 in its X ray powder diffraction PXRD collection of illustrative plates, wherein 2 θ value error ranges are 0.2.Crystal form E is that glycol dimethyl ether is added in lobaplatin dihydrate, and crystallization is precipitated in suspension stirring, isolates the crystallization, white powder, as the novel crystal forms E of lobaplatin are obtained after dry.Compared with existing lobaplatin and lobaplatin trihydrate, the novel crystal forms of the present invention have better stability, dissolubility, it is more suitable for preparing various forms of pharmaceutical preparations and storage, use, treating cancer can be preferably applied to and such as treat breast cancer, Small Cell Lung Cancer or chronic myelocytic leukemia.
Description
Technical field
The present invention relates to drug field, more particularly to a kind of novel crystal forms of lobaplatin and preparation method thereof and answering in drug
With belonging to pharmaceutical technology field.
Background technology
Lobaplatin (Lobaplatin, D19466) also known as lobaplatin are that the third generation platinum class after cis-platinum, carboplatin is anti-swollen
Tumor medicine, its chemical name is：Cis--[anti-form-1,2- cyclobutane bis- (methylamine)-N, N']-[(2S)-lactic acid-O1, O2]-platinum
(II), molecular formula C9H18N2O3Pt, molecular weight 397.34, shown in chemical structural formula such as following formula (1)：
Lobaplatin has alkanisation, belongs to alkylating agent (broad sense).With good antitumor action, such as in vitro AH135- tumors,
B16- melanomas, colon cancer 115 have good inhibiting effect in body mouse P338 leukaemia etc..The characteristics of lobaplatin is anti-
Cancer activity is strong, and toxicity is low, no cumulative toxicity and renal toxicity, and smaller to bone marrow toxicity, and platelet-free reduces disease, at present on
The injection lobaplatin in city is mainly used for the treatment of breast cancer, Small Cell Lung Cancer and chronic granulocytic leukemia.
The drug original side of grinding is that German Ace reaches Pharmacy stock Co., Ltd (ASTA Medica AG), original patent
EP0324154 describes the preparation method of lobaplatin for the first time.In subsequent patent EP0611303, and disclose the hydration of lobaplatin three
The preparation method of object, the product are crystallization aquatic products of the formation containing three hydrones by recrystallizing lobaplatin anhydride,
In that patent, it is indicated that the lobaplatin that the preparation method (embodiment 1a) described in EP0324154 obtains has hygroscopy, is easy to become
It is viscous, it is difficult to preparation be made.
Invention content
The technical problem to be solved by the present invention is to, previous lobaplatin anhydrides there are hygroscopy, be difficult to that preparation, stability is made
The problem of difference.The present invention provide a kind of bioavilability is high, stability is good, solubility is high, good fluidity, be not easy the moisture absorption become sticky,
The novel crystal forms of yield and the ideal lobaplatin of purity.
One skilled in the art will appreciate that same drug, crystal form is different, and bioavilability may also can have difference,
Its stability, mobility, compressibility etc. may also can be different, these physicochemical properties generate certain shadow to the application of drug
It rings.The polymorphic of drug has become drug research process and drug at essential heavy in yield and quality control and detection process
Component part is wanted, contributes to the selection of new drug compound bioactivity to the research of polymorph in pharmaceuticals, helps to provide biological profit
Expenditure increases clinical efficacy, contributes to selection and design and the determination of pharmaceutical preparation technology parameter of drug administration approach,
To improve production quality.
We have invented a kind of novel crystal forms of lobaplatin and preparation method thereof and in drug by continuous Improvement
Using.
Specifically, in order to solve the above technical problem, the present invention provides following technical solutions：
A kind of lobaplatin compound crystal, which is characterized in that its crystal form is E, PXRD collection of illustrative plates 2 θ angle value be about 6.61,
8.09, there is diffraction maximum at 12.38,13.03,15.40,16.66,17.47,19.07, wherein 2 θ value error ranges are 0.2.
Wherein, fusing point Tm.p..=214 ± 5 DEG C.
Wherein, which measured with DSC, is assessed with peak-peak, the rate of heat addition：10 DEG C/minute.
On the other hand, the method that the present invention provides the lobaplatin crystal, which is characterized in that include the following steps b)：
In lobaplatin dihydrate, glycol dimethyl ether is added, suspend stirring, and crystallization is precipitated, isolates the crystallization, dry
White powder, as the crystal form E of lobaplatin are obtained afterwards.
Preferably, wherein the preparation method of the lobaplatin dihydrate includes the following steps a)：
Suspension crystallization solvent is added in lobaplatin trihydrate, suspend stirring, and crystallization is precipitated, and after removing solvent, uses ether
Washing, vacuum drying obtain lobaplatin dihydrate crystallization.
Preferably, wherein in step a), the mass volume ratio of the lobaplatin trihydrate and recrystallisation solvent is three water of lobaplatin
Close object：Recrystallisation solvent=1:15-30.
Preferably, wherein in step a), the recrystallisation solvent is selected from methyl tertiary butyl ether(MTBE), toluene, ether, acetic acid fourth
Ester, 1,4- dioxane or normal heptane.
Preferably, wherein in step b), after isolating crystallization, washed before the drying with ether, the drying is vacuum
It is dry.
Preferably, wherein in step b), the suspension carries out at room temperature, and preferably suspend 45-50h.
Preferably, wherein the mass volume ratio of lobaplatin dihydrate and glycol dimethyl ether is two water of lobaplatin in step b)
Close object：Glycol dimethyl ether=1:15-30.
On the other hand, the present invention provides a kind of pharmaceutical composition, which is characterized in that using the lobaplatin crystal as activity
Ingredient.
Preferably, the amount containing lobaplatin crystal is 5mg, 10mg or 50mg in described pharmaceutical composition minimum unit.
Preferably, described pharmaceutical composition is any clinically acceptable pharmaceutical dosage form.
Preferably, the dosage form is freeze-drying preparation for injection.
On the other hand, the present invention provides the lobaplatin crystal or the pharmaceutical composition in preparing anticarcinogen
Application.
On the other hand, answering the present invention also provides the lobaplatin crystal or the medicine composite for curing cancer
With, it is preferable that it is used to treat breast cancer, Small Cell Lung Cancer or chronic granulocytic leukemia.
Raw material lobaplatin trihydrate used is prepared using the method for patent EP0611303 embodiments in the present invention.
Described pharmaceutical composition contains lobaplatin crystal form using lobaplatin crystal form above-mentioned as active constituent in minimum unit
Amount is 5mg, 10mg or 50mg.Drug can be made with one or more pharmaceutically acceptable carriers or excipient in lobaplatin novel crystal forms
Composition.Further, described pharmaceutical composition can be made into clinically any pharmaceutical dosage form suitable for raw material, including injection
Dosage form is given through parenteral routes such as skin form of administration, respiratory tract administration dosage form, cavity and other body parts mucosal drug delivery dosage forms
Pharmaceutically dosage form.Preferably injection freeze-dried powder.
The pharmaceutical carrier or excipient can be selected from it is following in it is one or more：Water for injection, mannitol, lactose,
Polyethylene glycols, Tween-80, propylene glycol, tartaric acid, citric acid, ascorbic acid, natrium adetate, mosatil, sulfurous acid
Hydrogen sodium, glucose, sodium chloride, soybean oil, soybean lecithin, yolk phospholipid, Distearoyl Phosphatidylethanolamine, dextran,
Glycine, glycerine.
The preparation method of above-mentioned composition and preparation is typically the known conventional method of those skilled in the art.The present invention's
Lobaplatin crystal form and the lobaplatin agent activity form of listing are all lobaplatins, i.e., anhydrous lobaplatin, therefore the production of the lobaplatin suitable for having listed
All diseases of product treatment.
Lobaplatin, that is, cis--[anti-form-1,2- cyclobutane bis- (methylamine)-N, N']-[(2S)-lactic acid-O1, O2]-platinum (II) belongs to
Alkylating agent, cytotoxic drug, also known as biological alkylating agent (BioalkylatingAgengts), can form carbonium ion in vivo
Or other compounds with active electrophilic groups, and then contain with the large biological molecule (DNA, RNA, enzyme) in cell
Covalent bond occurs for the group (such as amino, sulfydryl, hydroxyl, carboxyl, phosphate etc.) of abundant electronics, makes its loss of activity or makes
DNA molecular is broken, and leads to death of neoplastic cells, therefore antitumor activity is strong.Pharmacokinetic shows to be injected intravenously Lip river
After platinum, antitumor action is played in the form of total platinum and free platinum in serum, as anhydrous lobaplatin plays useful effect, with original
Material state is unrelated.
The present invention lobaplatin novel crystal forms, be based on amorphous state lobaplatin be easy deliquesce become sticky, stability it is poor, be not easy to store
Defect and the novel crystal forms developed have bioavilability high, and stability is good, the features such as being not easy to deliquesce, with lobaplatin trihydrate phase
Compare, it has surprisingly been found that it has solubility high compared to trihydrate, yield and purity is high, stability more preferably advantage.Therefore
The exploitation of the novel crystal forms contributes to selection and design and the determination of pharmaceutical preparation technology parameter of drug administration approach, to
Improve pharmaceutical production quality.The new lobaplatin compound of the present invention is highly stable at normal temperatures, be not easy the moisture absorption become sticky, mobility
Good, the operability in storage, transport and preparation and processing is substantially better than unformed shape lobaplatin.
Description of the drawings
Fig. 1：The x-ray diffraction pattern of lobaplatin novel crystal forms E；
Fig. 2：The differential thermal analysis DSC figures of lobaplatin novel crystal forms E；
Fig. 3：The differential thermal analysis TGA figures of lobaplatin novel crystal forms E.
Fig. 4：Crystal form is the x-ray diffraction pattern of the lobaplatin dihydrate of A；
Fig. 5：Crystal form is the molecule stereo structure perspective view of the lobaplatin dihydrate of A；
Fig. 6：Crystal form is the differential thermal analysis DSC figures of the lobaplatin dihydrate of A；
Fig. 7：Crystal form is the differential thermal analysis TGA figures of the lobaplatin dihydrate of A.
Specific implementation mode
The present invention provides that a kind of solubility is high, lobaplatin novel crystal forms of excellent in stability, is named as crystal form E.
On the one hand, the present invention provides a kind of lobaplatin novel crystal forms of crystal habit.The Lip river that just preparative separation of the present invention goes out below
Platinum crystal form E is described as follows：
Use manufacturer for the X-ray diffractometer of Bruker, model Bruker D8advance XRD, to lobaplatin crystalline substance
Type E is measured, and determination condition is：CuKa (40kv, 40mA), 2 °/min of sweep speed (2 θ values), 3 ° -45 ° of scanning range
(2 θ values), the absorption peak with following characteristics, see the table below 1, diffracting spectrum is as shown in Figure 1：
X-ray diffraction (PXRD) measurement result of 1 lobaplatin novel crystal forms E of table
The novel crystal forms E of the lobaplatin is NETZSCH, model NETZSCH DSC 204 F1, NETZSCH by manufacturer
The differential thermal analyzer of 209 F1 of TG carries out differential thermal analysis (DSC-TGA), and DSC figures are as shown in Fig. 2, TGA figures are as shown in Figure 3.As a result
It has been shown that, is measured with DSC, is assessed with peak-peak, fusing point Tm.p..=214 ± 5 DEG C, the rate of heat addition：10 DEG C/minute.Specially：DSC
Collection of illustrative plates has an exothermic peak at 214 ± 5 DEG C, judges in conjunction with TGA and 0611303 melting point data of European patent EP, which is melting point
Xie Feng, TGA collection of illustrative plates have 3.16% weightlessness before 150 DEG C, judge it for dissolvent residual in conjunction with DSC data.
On the other hand, the present invention provides a kind of system preparing lobaplatin novel crystal forms that are simple, easily operated, being suitble to amplification production
Preparation Method.
In a preferred embodiment, the preparation method of lobaplatin novel crystal forms E of the present invention, includes the following steps：
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate is weighed in container, 15-30ml organic solvents are added, in room
Warm low suspension stirs 45-50h, and filtering is washed with ether, and white powder, as lobaplatin dihydrate are obtained after vacuum drying；
Wherein, the organic solvent is selected from methyl tertiary butyl ether(MTBE), toluene, ether, butyl acetate, Isosorbide-5-Nitrae-dioxane or just
Heptane.
B, target crystal form is prepared：The lobaplatin dihydrate obtained by step a is weighed, is placed in container, glycol dinitrate is added
Ether, suspend stirring 45-50h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, is obtained in vain after vacuum drying
Color powder, as the novel crystal forms E of lobaplatin.
The mass volume ratio of lobaplatin dihydrate and glycol dimethyl ether is lobaplatin dihydrate in the step b：Second two
Diethylene glycol dimethyl ether=1:15-30.
Embodiment
By the following examples come illustrate the present invention lobaplatin crystal form E preparation method and each novel crystal forms screening
Separation process and its identification and performance measurement.
Embodiment one：The screening of each crystal form is analyzed
The volatilization crystallisation screening of 1.1 room temperature
It takes 20mg lobaplatin trihydrate samples to be put into 10ml sample bottles, 3ml absolute ethyl alcohols or absolute methanol is added, fully
It after dissolving, is placed under 25 DEG C of environment and slowly volatilizees, obtain solid dried object, carry out PXRD measurement.As a result 2 be see the table below：
2 room temperature of table volatilization crystallization trial result
| Number | Solvent | PXRD (possible crystal form number) |
| 1-1 | Absolute ethyl alcohol | B |
| 1-2 | Absolute methanol | B |
The result shows that：The crystal form obtained in absolute methanol and absolute ethyl alcohol is learnt that it is same crystal form through comparing, is temporarily ordered
Entitled crystal form B.
1.2 suspended crystallization methods screen
It takes 20mg lobaplatin trihydrate samples to be put into 10ml sample bottles, the following organic solvents of 4ml is added, are prepared into suspension
Liquid is placed under 25 DEG C of environment after shaking 1.5h and removes solvent, and PXRD measurement is carried out after solid drying.As a result 3 be see the table below：
3 suspension crystallization test result of table
The result shows that：Crystal form obtained by suspension crystallization has 9 kinds, is temporarily named as crystal form A, B, C, D, E, G, H, I, L.
1.3 solventing-out process screen
20mg lobaplatin trihydrate samples are taken, is dissolved in 3ml absolute methanols or absolute ethyl alcohol and is configured to solution, thereto
Following organic solvents are gradually added, until solid is precipitated, supernatant is removed, PXRD measurement is carried out after solid drying.As a result it sees below
Table 4：
4 dilution crystallization test result of table
The result shows that：Crystal form obtained by suspension crystallization has 7 kinds, is temporarily named as crystal form F, J, K, M, N, O, P.
The characterization of 1.4 each crystal forms
To crystal form A-P samples carry out PXRD measurement and DCS, TGA characterization, wherein used each instrument title, model and
Producer is as shown in table 5 below.
Each instrument model when table 5 characterizes crystal form and manufacturer
Measurement result is as follows：
Crystal form A, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 11.04,12.32,12.61,13.85,15.14,
15.55、16.68、17.67、17.86、19.03、20.06、21.00、22.68、22.92、23.76、25.39、25.58、
26.37、26.77、27.00、27.71、28.13、29.71、31.42、31.94、32.89、34.29、34.60、36.10、
36.93, there is diffraction maximum at 37.66,40.78,43.41, wherein 2 θ value error ranges are 0.2；
Crystal form A, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 220 ± 5 DEG C.
Crystal form B, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.25,9.77,11.70,13.13,15.28,16.48,
17.22、17.74、19.01、19.56、22.28、23.72、24.04、24.30、25.62、26.20、28.57、30.22、30.61
There is diffraction maximum at place, wherein 2 θ value error ranges are 0.2；
Crystal form B, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 230 ± 5 DEG C.
Crystal form C, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.79,8.07,12.24,12.61,13.50,16.50,
17.83, have at 18.32,18.79,20.09,21.64,22.27,23.19,24.73,27.34,28.35,29.12,31.92 and spread out
Peak is penetrated, wherein 2 θ value error ranges are 0.2；
Crystal form C, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 228 ± 5 DEG C.
Crystal form D, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.76,11.07,12.35,12.65,13.88,15.18,
15.56、16.68、17.70、17.90、20.08、21.02、22.70、22.92、25.41、25.64、26.41、26.79、
27.02, there is diffraction maximum at 28.15,31.44,31.96,32.96,34.34,34.62,36.93,40.82,43.46, wherein 2 θ
It is 0.2 to be worth error range；
Crystal form D, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 218 ± 5 DEG C.
Crystal form E, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.61,8.09,12.38,13.03,15.40,16.66,
17.47, there is diffraction maximum at 19.07, wherein 2 θ value error ranges are 0.2；
Crystal form E, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 214 ± 5 DEG C.
Crystal form F, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.21,11.60,12.99,15.24,16.44,17.11,
17.55、18.42、19.01、19.20、19.42、21.81、22.17、22.42、23.33、23.85、24.18、24.40、
24.77、25.46、25.98、26.13、27.89、28.42、29.03、30.32、31.17、31.94、33.30、36.20、
37.62, there is diffraction maximum at 39.66, wherein 2 θ value error ranges are 0.2；
Crystal form F, it is characterised in that DSC collection of illustrative plates nearby has exothermic peak at 229 ± 5 DEG C.
Crystal form G, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.62,10.82,11.03,12.26,12.59,13.82,
15.12、15.57、16.59、17.43、17.65、18.48、19.46、20.11、20.37、21.01、22.66、22.86、
24.60、25.40、26.33、26.77、27.00、28.11、29.79、31.42、31.94、32.87、34.25、34.58、
36.06, there is diffraction maximum at 40.76,42.75,43.39, wherein 2 θ value error ranges are 0.2.
Crystal form H, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.35,8.53,8.68,12.97,15.24,17.41,
18.40, there is diffraction maximum at 19.13,19.48,20.37,24.68,25.41,30.33,31.66,36.34, wherein 2 θ value errors
Ranging from 0.2.
Crystal form I, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.75,8.39,11.07,11.59,12.32,12.63,
12.99、15.20、16.80、17.07、17.57、19.14、19.46、21.00、22.13、22.84、23.29、23.77、
24.22, there is diffraction maximum at 25.82,26.76,28.38,30.34,30.83,31.90,33.63,36.32,38.47, wherein 2 θ
It is 0.2 to be worth error range.
Crystal form J, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 5.94,8.35,9.87,13.05,15.28,16.66,
19.15, there is diffraction maximum at 22.22,22.68,25.09,30.71,33.56, wherein 2 θ value error ranges are 0.2.
Crystal form K, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.29,11.02,12.31,12.61,13.84,15.14,
15.53、16.70、17.66、19.05、20.06、20.98、22.68、22.90、25.60、26.37、26.77、26.98、
27.68、28.23、29.75、31.40、31.88、32.90、33.81、34.29、34.60、36.10、36.84、37.64、
39.93, there is diffraction maximum at 40.76,41.51,42.36,42.70,43.39, wherein 2 θ value error ranges are 0.2.
Crystal form L, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.71,7.91,10.75,11.84,14.06,14.29,
15.85、16.78、17.29、19.76、20.20、20.63、21.08、21.58、21.89、22.17、23.87、25.09、
26.83, there is diffraction maximum at 27.02,28.73,29.18,29.92,30.56,31.61,33.95,40.33,41.33, wherein 2 θ
It is 0.2 to be worth error range.
Crystal form M, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 8.05,13.03,15.20,16.19,17.47,18.77,
19.32, there is diffraction maximum at 24.06, wherein 2 θ value error ranges are 0.2.
Crystal form N, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 7.94,12.67,14.83,16.32,17.16,18.71,
21.83, there is diffraction maximum at 22.44,24.10,24.89,27.97,30.02,30.48, wherein 2 θ value error ranges are 0.2
Crystal form O, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.75,8.15,16.29,18.95,22.23,24.52,
There is diffraction maximum at 29.93, wherein 2 θ value error ranges are 0.2.
Crystal form P, it is characterised in that PXRD collection of illustrative plates 2 θ values be about 6.61,8.17,13.34,16.52,20.10,24.97,
27.02, there is diffraction maximum at 33.99,41.06, wherein 2 θ value error ranges are 0.2.
1.5 repetitions, amplification test
Crystal form A-P is further selected, 100mg amplifications is carried out respectively according to above-mentioned " screening of 1.2 suspended crystallization methods " and repeats to try
It tests, verifies the repeatability of crystal form.As a result 6 be see the table below：
Table 6 repeats test result
The result shows that：Crystal form A-F stablizes, and the amplification that crystal form G-P has is difficult, and some appearance crystal phenomenon are unsuitable for into one
Step is investigated.
That is, the methods of comprehensive room temperature volatilization, suspension crystallization, dilution crystallization carry out crystallization screening to raw material, use
By analysing and comparing to collection of illustrative plates after PXRD characterizations, there may be 16 kinds of crystal form A-P for preliminary judgement lobaplatin；By repeating, putting
Big verification, it is final to determine that crystal form A-F is repeatable preferable, for opposite stable crystal form；The yield that other crystal forms have is relatively low, it is difficult to carry out
Amplification production；Some appearance crystal phenomenon infer that it is unstable crystal form.Therefore, crystal form A-F is selected, is further carried out comprehensive
It investigates.
Embodiment two：It is named as the preparation of the lobaplatin novel crystal forms of crystal form E
Preparation example 1
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, 30ml toluene is added, hangs at room temperature
Floating stirring 48h, filtering are washed with ether, and white powder 1.73g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 15ml, suspend stirring 48h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.89g, as the novel crystal forms E of lobaplatin.
Preparation example 2
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, 15ml methyl tertiary butyl ether(MTBE)s are added, in
Room temperature low suspension stirs 48h, and filtering is washed with ether, and white powder 1.84g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 20ml, suspend stirring 45h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.87g, as the novel crystal forms E of lobaplatin.
Preparation example 3
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, 20ml butyl acetates are added, in room temperature
Low suspension stirs 50h, and filtering is washed with ether, and white powder 1.68g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 30ml, suspend stirring 45h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.90g, as the novel crystal forms E of lobaplatin.
Preparation example 4
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, addition 25ml1,4- dioxane, in
Room temperature low suspension stirs 45h, and filtering is washed with ether, and white powder 1.76g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 25ml, suspend stirring 46h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.85g, as the novel crystal forms E of lobaplatin.
Preparation example 5
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, 30ml normal heptanes are added, at room temperature
Suspend stirring 45h, and filtering is washed with ether, and white powder 1.75g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 25ml, suspend stirring 46h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.84g, as the novel crystal forms E of lobaplatin.
Preparation example 6
A, lobaplatin dihydrate is prepared：Lobaplatin trihydrate 2g is weighed in container, 15m ether is added, hangs at room temperature
Floating stirring 45h, filtering are washed with ether, and white powder 1.78g, as lobaplatin dihydrate are obtained after vacuum drying；
B, target crystal form is prepared：The lobaplatin dihydrate 1g obtained by step a is weighed, is placed in container, ethylene glycol two is added
Methyl ether 25ml, suspend stirring 46h at room temperature, and crystallization is precipitated, filters to isolate the crystallization, is washed with ether, after vacuum drying
Obtain white powder 0.85g, as the novel crystal forms E of lobaplatin.
The sample that step a) is prepared in embodiments above 1-6 is carried out according in above-described embodiment one 1.4 method
After XRD diffractions, the crystal form for being accredited as 6 kinds of samples is identical, which is A, and appraising datum is as follows.
The crystal form is A, and appraising datum is as follows.
The crystal form is the lobaplatin dihydrate of A, the absorption peak with feature shown in following table 7, diffraction spectrogram such as Fig. 4 institutes
Show.
7 crystal form of table is lobaplatin dihydrate X-ray diffraction (PXRD) measurement result of A
| Peak sequence | 2 θ values (about) of the angle of diffraction | Crystal face is away from d (about) | Relative intensity (about) |
| 1 | 11.04 | 8.01 | 66.9 |
| 2 | 12.32 | 7.18 | 86.3 |
| 3 | 12.61 | 7.01 | 51.3 |
| 4 | 13.85 | 6.39 | 22.2 |
| 5 | 15.14 | 5.85 | 100 |
| 6 | 15.55 | 5.69 | 17.4 |
| 7 | 16.68 | 5.31 | 35 |
| 8 | 17.67 | 5.02 | 54.5 |
| 9 | 19.03 | 4.66 | 4.8 |
| 10 | 20.06 | 4.42 | 16.8 |
| 11 | 21.00 | 4.23 | 75.9 |
| 12 | 22.68 | 3.92 | 25.4 |
| 13 | 22.92 | 3.88 | 28.2 |
| 14 | 23.76 | 3.74 | 2 |
| 15 | 25.58 | 3.48 | 7.8 |
| 16 | 26.77 | 3.33 | 37.4 |
| 17 | 27.00 | 3.30 | 22.9 |
| 18 | 27.71 | 3.22 | 8.3 |
| 19 | 28.13 | 3.17 | 19.2 |
| 20 | 29.71 | 3.00 | 8.4 |
| 21 | 31.42 | 2.84 | 33.5 |
| 22 | 31.94 | 2.80 | 25.1 |
| 23 | 32.89 | 2.72 | 8.9 |
| 23 | 34.60 | 2.59 | 17.3 |
| 25 | 36.93 | 2.43 | 10.3 |
| 26 | 37.66 | 2.39 | 7.3 |
| 27 | 40.78 | 2.21 | 12.3 |
| 28 | 43.41 | 2.08 | 9.8 |
Its characteristic peak is as follows in PXRD collection of illustrative plates：2 θ values be about 11.04,12.32,12.61,13.85,15.14,15.55,
16.68、17.67、17.86、19.03、20.06、21.00、22.68、22.92、23.76、25.39、25.58、26.37、
26.77、27.00、27.71、28.13、29.71、31.42、31.94、32.89、34.29、34.60、36.10、36.93、
37.66, there is diffraction maximum at 40.78,43.41, wherein 2 θ value error ranges are 0.2；
By carrying out X-ray single crystal diffraction experiment, crystal is in water white transparency column, belongs to rhombic system, space group is
P212121, cell parameter：A=10.601 (2), b=14.020 (3),α=β=γ=90.0 °, structure cell body
ProductAsymmetry unit number Z=4 in structure cell；
Diffracted intensity data, CuK are collected with Bruker SMART APEX-II diffractometersαRadiation, graphite monochromator are singly led
Pipe diameter ф=0.50mm, crystal and ccd detector distance d=60.3mm, pipe press 40kV, pipe stream 30mA, scan mode：φ/
ω is scanned, and it is 5844 to collect total diffraction points, and independent diffraction points are 2376, observable points (| F | 2 >=2 σ | F | 2) be
2376.
Crystal structure is parsed using direct method (Shelxs97), all 17 non-hydrogen atom positions is can get, uses minimum
Square law correcting principle parameter and differentiation atomic species, use geometric calculation and difference Fourier method to obtain whole hydrogen atoms
Position, final Reliability factor R1=0.0569, wR2=0.1491 (w=1/ σ | F |2), S=1.077.It is final to determine stoichiometry
Formula is C9H18N2O3Pt·2H2O, it is 433.36 to calculate molecular weight, calculates crystalline density 1.975g/cm3.It can be true through structure elucidation
Fixed lobaplatin novel crystal forms obtained are lobaplatin dihydrate, shown in molecular structure such as following formula (2)：
The crystal form is that the molecule stereo structure perspective view of the lobaplatin dihydrate of A is as shown in Figure 5.
In addition, the lobaplatin dihydrate that the crystal form is A by manufacturer is NETZSCH, model NETZSCH DSC
The differential thermal analyzer progress differential thermal analysis (DSC-TGA) of 204 F1,209 F1 of NETZSCH TG, DSC scheme as shown in fig. 6, TGA
Figure is as shown in Figure 7.The results show that being measured with DSC, assessed with peak-peak, fusing point Tm.p..=220 ± 5 DEG C, the rate of heat addition：10
DEG C/minute.Specially：DSC collection of illustrative plates has a wide endothermic peak at 117 DEG C or so, judges that the peak may be in conjunction with monocrystalline and TGA data
2 crystallizations water are lost to generate；There is an exothermic peak at 220 ± 5 DEG C, sentences in conjunction with TGA and 0611303 melting point data of European patent EP
Disconnected, which is fusion and decomposition peak.TGA collection of illustrative plates has 9.49% weightlessness before 150 DEG C, is shown to be and loses 2 crystallizations water generations.
On the other hand, sample embodiments above 1-6 being prepared according in above-described embodiment one 1.4 method
After carrying out XRD diffractions, the crystal form for being accredited as 6 kinds of samples is identical, and characteristic peak is as follows：It is in 2 θ angle value in PXRD collection of illustrative plates
6.61, there is diffraction maximum at 8.09,12.38,13.03,15.40,16.66,17.47,19.07, wherein 2 θ value error ranges are
0.2.This crystal form is named as E types.
Embodiment three：Product property measures and comparative analysis
1, test specimen
Sample 1-6：1-6 preparation methods of the embodiment of the present invention obtain；
Contrast sample 1：It is as follows using lobaplatin, specific preparation method made from patent EP0324154 embodiment 1a methods：
3.8g (0.01mol) is cis--and [anti-form-1,2- cyclobutyl bis- (methylamine)-N, N']-dichloro platinum (II) is suspended in 20ml
In water, 40 DEG C are heated to, 3.39g (0.02mol) silver nitrate is added thereto.After stirring 1.5 hours, cools down, filter out in refrigerator
10ml water washings are used in combination in the silver nitride precipitation of precipitation, and filtrate is by containing 100ml basic ion exchange columns, with 150ml water washings.
Then it is added drop-wise in the Pfansteihl of 4.5g (0.01mol, 20% aqueous solution).It is after stirring 3 days at room temperature, reaction mixture is dense
Contracting, after be dissolved in methanol and be added activated carbon stirring decoloration.Activated carbon is filtered off again, ether, rapid concentration are added in filtrate
Obtain solid, as unformed shape lobaplatin.
Contrast sample 2：Using lobaplatin trihydrate, specific preparation method made from patent EP0611303 embodiment methods
It is as follows：
3.8g (0.01mol) is cis--and [anti-form-1,2- cyclobutyl bis- (methylamine)-N, N']-dichloro platinum (II) is suspended in 20ml
In water, 40 DEG C are heated to, 3.39g (0.02mol) silver nitrate is added thereto.After stirring 1.5 hours, cools down, filter out in refrigerator
10ml water washings are used in combination in the silver nitride precipitation of precipitation, and filtrate is by containing 100ml basic ion exchange columns, with 150ml water washings.
Then it is added drop-wise in the Pfansteihl of 4.5g (0.01mol, 20% aqueous solution).After stirring 3 days at room temperature, reaction mixture is concentrated
To about 20ml, stood overnight in refrigerator.The crystallization that suction strainer is precipitated, filtrate concentration, refrigerator is stood overnight, and crystallization is precipitated, then
Filter collection after merging crystallization, is recrystallized, gained crystal is lobaplatin trihydrate with 20ml water/acetone (1/1, V/V).
2, Morphological Identification
Contrast sample 1：Obtained lobaplatin is amorphous state；
Contrast sample 2：By X-ray diffraction, PXRD collection of illustrative plates 2 θ values be about 6.71,8.35,12.89,15.14,
16.74、17.45、19.01、19.40、22.07、22.76、23.16、24.30、25.21、25.74、27.08、30.26、30.79
Place has diffraction maximum, 2 θ value error ranges to be less than 0.2, its fusing point is 210 DEG C (decomposition) described in patent EP0611303；
Inventive samples 1-6：As previously mentioned, by X-ray diffraction, PXRD collection of illustrative plates 2 θ values be about 6.61,8.09,
12.38, diffraction maximum, 2 θ value error ranges at 13.03,15.40,16.66,17.47,19.07 are less than 0.2；DSC collection of illustrative plates is aobvious
Show at 214 ± 5 DEG C there is exothermic peak, judge in conjunction with TGA and document melting point data, which is fusion and decomposition peak, shows sample 1-6
For same crystal form, the also as novel crystal forms E of lobaplatin.
3, solubility is investigated
Compound concentration is 60 μ g/ml respectively, the lobaplatin three of 80 μ g/ml, 200 μ g/ml, 400 μ g/ml, 800 μ g/ml are hydrated
Object solution makes standard curve by HPLC legal systems, and gained calibration curve equation is Y=4.8641X+20.5794, R=0.9998.
Saturated aqueous solution (suspension) is made in the sample 1 of lobaplatin novel crystal forms and contrast sample 2, sets 25 DEG C of shaking table concussion 6h, then mistake
Filter dilutes suitable multiple, carries out HPLC analyses.Solubility results such as the following table 8：
8 solubility of table investigates result
| Crystal form | Sample 1 | Contrast sample 2 |
| Solubility (mg/ml) | 14.0730 | 10.3271 |
The result shows that：Lobaplatin compound dissolubility produced by the present invention is better than lobaplatin trihydrate.
4, lobaplatin novel crystal forms quality versus studies
Sample 1-6, each 20mg of contrast sample 1-2 are taken, is with product moisture, impurity content, active component content, yield etc.
Index investigates product quality and yield.As a result 9 be see the table below：
9 lobaplatin novel crystal forms quality versus of table studies
The above results show that compared with lobaplatin anhydride and lobaplatin trihydrate, the lobaplatin novel crystal forms E that the present invention obtains has
Have the characteristics that content is high, impurity is low, yield is good.
Note 1：Content assaying method：According to high effective liquid chromatography for measuring：Chromatographic condition：Use octadecylsilane chemically bonded silica
For filler, with potassium dihydrogen phosphate：Acetonitrile=92:8 be mobile phase, Detection wavelength 210nm, 40 DEG C of column temperature, theoretical plate
Number should be mended by the calculating of lobaplatin peak less than 1000, and lobaplatin peak meets the requirements with impurity peaks separating degree；The preparation of reference substance solution：Take Lip river
Platinum trihydrate reference substance 10mg, it is accurately weighed to set in 50ml measuring bottles, it is diluted with water to scale, shakes up to obtain the final product；Test solution
Preparation：Sample each 20mg is taken, it is accurately weighed, it sets respectively in 100ml measuring bottles, is diluted with water to scale, shake up to obtain the final product；Measure and
As a result：Precision measures reference substance and each 10 μ l of sample solution, is injected separately into liquid chromatograph, records chromatogram, by external standard method with
Calculated by peak area is calculated to obtain the final product by anhydride, critical field 97.0%-102%.
Note 2：Determination of foreign matter method：Lobaplatin, 1,2- diaminomethyls cyclobutane (CBMA), lactic acid etc. have been measured with thin-layer chromatography
Impurity content know and unknown.Solvent：Ethyl alcohol：Chloroform：25% ammonium hydroxide：Water=53：39：15：1.5 (volume ratios), thin layer
Chromatoplate：Silica gel 60F25410 × 10 lamellaes.After expansion in iodine vapor with 0.3% ninhydrin reagent and to nitroso diformazan
Aniline reagents develop the color, and check impurity CBMA and unknown impuritie.
Note 3：Determination of moisture method：It is measured using KarlFischer methods.Dihydrate moisture content theoretical amount is
8.77%, trihydrate moisture content theoretical amount is 11.96%.
5, study on the stability
Sample made from the embodiment of the present invention 1, contrast sample 2 are respectively placed in 60 DEG C of baking ovens, relative humidity is about
In the environment of 95%, in the light stability test case that illumination is about 4500lux, sample is taken out after 5 days, 10 days and is carried out
PXRD is tested and HPLC analyses, to investigate the stability of sample under the high temperature conditions.As a result 10 be see the table below：
10 estimation of stability result of table
Above-mentioned test result shows that lobaplatin of the invention is novel crystal forms, and solubility is higher than lobaplatin trihydrate, yield and pure
Spend ideal, from the point of view of result is investigated in high temperature, high humidity, illumination, lobaplatin novel crystal forms stability is good, and no crystal phenomenon occurs,
HPLC and significant change does not occur, illustrates that lobaplatin of the present invention is newly brilliant the result shows that active constituent content is better than lobaplatin trihydrate
Type stability is good.
Claims (21)
1. a kind of lobaplatin compound crystal, which is characterized in that its crystal form be E, PXRD collection of illustrative plates 2 θ angle value be 6.61,8.09,
12.38, there is diffraction maximum at 13.03,15.40,16.66,17.47,19.07, wherein 2 θ value error ranges are 0.2.
2. lobaplatin compound crystal as described in claim 1, which is characterized in that fusing point Tm.p..=214 ± 5 DEG C.
3. the method for preparing lobaplatin compound crystal described in claims 1 or 2, which is characterized in that include the following steps 1)：In Lip river
In platinum dihydrate, glycol dimethyl ether is added, crystallization is precipitated in suspension stirring, isolates the crystallization, white powder is obtained after dry
End, as the crystal form E of lobaplatin；
Wherein, the preparation method of the lobaplatin dihydrate includes the following steps a)：It is added and suspends in lobaplatin trihydrate
Recrystallisation solvent, suspend stirring, and crystallization is precipitated, and after removing solvent, is washed with ether, and vacuum drying obtains the lobaplatin dihydrate knot
It is brilliant；Wherein, the recrystallisation solvent is selected from methyl tertiary butyl ether(MTBE), toluene, ether, butyl acetate, Isosorbide-5-Nitrae-dioxane or positive heptan
Alkane.
4. method as claimed in claim 3, wherein in step a), the mass body of the lobaplatin trihydrate and recrystallisation solvent
Product is than being lobaplatin trihydrate：Recrystallisation solvent=1:(15-30)g/ml.
5. method as described in claim 3 or 4, wherein in step 1), after isolating crystallization, washed before the drying with ether
It washs, the drying is vacuum drying.
6. method as described in claim 3 or 4, wherein in step 1), the suspension carries out at room temperature.
7. method as claimed in claim 5, wherein in step 1), the suspension carries out at room temperature.
8. method as described in claim 3 or 4, wherein in step 1), described suspend is suspension 45-50h.
9. method as claimed in claim 5, wherein in step 1), described suspend is suspension 45-50h.
10. method as described in claim 3 or 4, which is characterized in that lobaplatin dihydrate and ethylene glycol two in the step 1)
The mass volume ratio of methyl ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
11. method as claimed in claim 5, which is characterized in that lobaplatin dihydrate and glycol dinitrate in the step 1)
The mass volume ratio of ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
12. method as claimed in claim 6, which is characterized in that lobaplatin dihydrate and glycol dinitrate in the step 1)
The mass volume ratio of ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
13. the method for claim 7, which is characterized in that lobaplatin dihydrate and glycol dinitrate in the step 1)
The mass volume ratio of ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
14. method as claimed in claim 8, which is characterized in that lobaplatin dihydrate and glycol dinitrate in the step 1)
The mass volume ratio of ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
15. method as claimed in claim 9, which is characterized in that lobaplatin dihydrate and glycol dinitrate in the step 1)
The mass volume ratio of ether is lobaplatin dihydrate：Glycol dimethyl ether=1:(15-30)g/ml.
16. a kind of pharmaceutical composition, which is characterized in that using lobaplatin compound crystal as claimed in claim 1 or 2 as activity at
Point.
17. pharmaceutical composition as claimed in claim 16, which is characterized in that contain Lip river in described pharmaceutical composition minimum unit
The amount of platinum compounds crystal is 5mg, 10mg or 50mg.
18. the pharmaceutical composition as described in claim 16 or 17, which is characterized in that described pharmaceutical composition be it is any clinically
Acceptable pharmaceutical dosage form.
19. the pharmaceutical composition as described in claim 16 or 17, which is characterized in that the dosage form of described pharmaceutical composition is injection
Use lyophilized preparation.
20. lobaplatin compound crystal as claimed in claim 1 or 2 or claim 16-19 any one of them pharmaceutical compositions
Application of the object in preparing anticarcinogen.
21. application according to claim 20, wherein the cancer refers to breast cancer, Small Cell Lung Cancer or chronic granulocyte
Property leukaemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279550.1A CN105218587B (en) | 2014-06-20 | 2014-06-20 | A kind of lobaplatin crystal, preparation method and medicinal application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279550.1A CN105218587B (en) | 2014-06-20 | 2014-06-20 | A kind of lobaplatin crystal, preparation method and medicinal application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105218587A CN105218587A (en) | 2016-01-06 |
| CN105218587B true CN105218587B (en) | 2018-08-14 |
Family
ID=54987917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410279550.1A Active CN105218587B (en) | 2014-06-20 | 2014-06-20 | A kind of lobaplatin crystal, preparation method and medicinal application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105218587B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110790791A (en) * | 2018-08-02 | 2020-02-14 | 贵州益佰制药股份有限公司 | Anhydrous crystal of lobaplatin, preparation method and pharmaceutical application |
| JP7180923B2 (en) * | 2018-09-01 | 2022-11-30 | ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド | Platinum-based compound phosphate and method for producing the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023335A (en) * | 1988-01-09 | 1991-06-11 | Asta Pharma Aktiengesellschaft | 1,2-bis (aminomethyl) cyclobutane-platinum complexes |
| CN1120046A (en) * | 1994-04-15 | 1996-04-10 | Asta药物股份公司 | Lobaplatin-Trihydrat |
| CN102020679A (en) * | 2010-11-24 | 2011-04-20 | 贵州益佰制药股份有限公司 | Method for preparing lobaplatin trihydrate by usingoxalate |
| CN103467528A (en) * | 2013-08-21 | 2013-12-25 | 江苏奥赛康药业股份有限公司 | Preparation method of lobaplatin |
-
2014
- 2014-06-20 CN CN201410279550.1A patent/CN105218587B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023335A (en) * | 1988-01-09 | 1991-06-11 | Asta Pharma Aktiengesellschaft | 1,2-bis (aminomethyl) cyclobutane-platinum complexes |
| CN1120046A (en) * | 1994-04-15 | 1996-04-10 | Asta药物股份公司 | Lobaplatin-Trihydrat |
| CN102020679A (en) * | 2010-11-24 | 2011-04-20 | 贵州益佰制药股份有限公司 | Method for preparing lobaplatin trihydrate by usingoxalate |
| CN103467528A (en) * | 2013-08-21 | 2013-12-25 | 江苏奥赛康药业股份有限公司 | Preparation method of lobaplatin |
Non-Patent Citations (1)
| Title |
|---|
| 洛铂的合成;冯秀珍等;《中国现代应用药学》;20061225(第06期);第165-166页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105218587A (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6967625B2 (en) | How to Isolate Gemcitabine Phosphate Diastereoisomers | |
| ES2765648T3 (en) | Procedure for the preparation of dicycloplatin | |
| CN102791719A (en) | Crystal of diamine derivative and method of producing same | |
| CN108472269A (en) | With the pharmaceutically acceptable β of improved property-guanidinopropionic acid salt and application thereof | |
| WO2017107985A1 (en) | Crystals of quinazoline derivative and preparation method therefor | |
| RU2648990C1 (en) | Lobaplatin crystals, methods of production and applications in pharmaceuticals | |
| CN105440082B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
| CN105198932B (en) | Lobaplatin dihydrate, preparation method and medicinal application | |
| CN105218587B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
| CN104918937B (en) | Sibutramine Hydrochloride for Buddhist nun and the crystal formation of solvate thereof, its preparation method, containing their medical composition and its use | |
| CN105330702B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
| CN105440083B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
| CN105198933B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
| EP3330267A1 (en) | Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof | |
| CN108516966A (en) | Crystal form of Dapagliflozin and its preparation method and application | |
| CN116018343A (en) | Crystal form of pyridopyrimidine compound | |
| CN110790791A (en) | Anhydrous crystal of lobaplatin, preparation method and pharmaceutical application | |
| CN104628727B (en) | A kind of crystal form of Pralatrexate and preparation method thereof | |
| CN116655700A (en) | Lobaplatin crystal and preparation method and application thereof | |
| CN112166107B (en) | Crystal forms of 4-phenylthiazole derivative and preparation method thereof | |
| CN111278828B (en) | Novel crystal form of Baratinib phosphate and preparation method thereof | |
| CN101497640B (en) | Novel crystal form of clofarabine | |
| CN117466913A (en) | Crystal forms of 5, 6-dihydrobenzo [ f ] imidazo [1,2-d ] [1,4] oxazepine compound and preparation method thereof | |
| CN114341113A (en) | Novel crystal form of acetylated eltrombopag and preparation method thereof | |
| BR112017021590B1 (en) | DICYCLOPLATIN PREPARATION PROCESS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231101 Address after: 570100 Haikou National High tech Industrial Development Zone A-6, Haikou City, Hainan Province Patentee after: Hainan Changan International Pharmaceutical Co.,Ltd. Address before: 550008 No. 220-1 Baiyun Avenue, Guizhou, Guiyang Patentee before: GUIZHOU YIBAI PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |